Jonathan Rigby has been appointed CEO of Immune Regulation, a London-based clinical stage biotech focussed on for inflammatory and immunological diseases.
Based in the US, Mr Rigby, who also joins the Board of Directors, brings decades of pharma, biotech and drug delivery technology experience.
In 2011, he became the CEO of SteadyMed Therapeutics and focused the company on the development of drug device combination products to treat Pulmonary Hypertension.
He led the company through a Nasdaq listing in 2015 and a public-to-public company sale to United Therapeutics in late 2018.
In 2006 he cofounded Zogenix, a specialty pharmaceutical company now focused on the development and commercialisation of drug products to treat rare diseases and was instrumental in its listing on Nasdaq in 2010.
Earlier in his career, he held commercial and business development positions of increasing responsibility at large pharmaceutical companies including Merck and Bristol Myers Squibb and Profile Therapeutics (now Phillips Medical).
He replaces outgoing Chief Executive Richard Nagle, who has led the business since 2017.
Immune Regulation Chairman, Dr Dominik Escher, said that Mr Rigby is “the ideal candidate to lead the next stage of clinical development of our two key therapies in immune system resetting”.
Mr Rigby said: “The Company has first-in-class immune-resetting therapies with a broad potential to treat autoimmune diseases. For example, IRL201805 and IRL201104 have shown considerable efficacy in preclinical and human clinical studies in rheumatoid arthritis and asthma / severe allergy respectively.
“We are also in the early stages of assessing the potential of IRL1104 to reduce lung inflammation which may be a consequence in patients infected by the COVID-19 virus.”